Passive Money Arrives | Google Backs Intel | Weight Loss Leap

The Nasdaq is leading the rebound with semiconductors at the front. That's a sharp reversal from Friday's selloff.

What's surprising is what investors are overlooking. Oil is higher, yields remain elevated, and Middle East tensions persist.

For now, investors are buying the dip rather than fearing the headlines.

The real test arrives Wednesday. Inflation data will determine whether Friday was a brief reset or the start of a larger pullback. Until then, AI has reasserted itself as the market's primary story.

Today morning, Trump intervened and called for an immediate halt. Iran declared it had "delivered a painful response" and ended operations. Israel stopped striking Iran but kept hitting southern Lebanon. The market bounced on the news.

The ceasefire was restored under pressure, not agreement. Iran's earlier statement that a deal with Trump is "no longer feasible" has not been taken back. Israel is still active in Lebanon. Hezbollah fired rockets after the halt. The next trigger is already forming.

The April rally was built on one foundational assumption. The ceasefire holds and a deal eventually follows. That assumption has now been violated by both sides and patched under duress. Patched under duress is not the same thing as restored.

What Has Not Changed

The bounce is real. But the underlying setup is more fragile than it was before Sunday night.

The Oil Signal

WTI holding below $93 through Tuesday means markets are absorbing the partial restoration. Oil climbing back toward $95 means the Lebanon front is being priced as the next escalation trigger. That tells you everything about how Wednesday's CPI will be read.

Marvell Technology (MRVL) will join the S&P 500 on June 22. The stock surged more than 13 percent today on the news. The timing is the most useful single mechanical event for the AI infrastructure trade available after last week's selloffs.

Here is why this matters beyond one stock. Index funds that track the S&P 500 must buy Marvell before June 22. No choice. No earnings required. No macro conditions needed. Just mandatory buying driven by index mechanics.

That mechanical floor is what every other chip name that sold off Friday does not have. Marvell fell hard last week. It now has a built-in buyer arriving before the month ends regardless of what CPI prints or what Warsh says.

The irony is sharp. S&P refused to change its rules for SpaceX this week. The standard process delivered Marvell a named passive demand event through the normal route.

The Ripple

A broad chip sector recovery on Marvell's news names position-driven selling as Friday's primary cause rather than a genuine AI demand reset. That distinction matters for everything priced in the sector right now.

Cisco was once the MOST valuable company on Earth. Then it fell 80% - and investors waited 25 YEARS just to break even.

A Wall Street legend is out with a new warning: "It's about to happen again." He says many of today's overhyped AI darlings - stocks sitting in almost every 401(k) in America - could lose up to HALF their value or more.

He just went on camera with the names. Watch his talk here before it's too late.

For three years the AI chip supply chain had one foundry at its center. TSMC makes the chips. Everyone waits for TSMC. That structure just developed its first visible crack.

Google (GOOGL) placed an order with Intel (INTC) to manufacture millions of its AI chips in 2028. Intel shares rose more than 9 percent on the news. Nvidia (NVDA) is also evaluating whether Intel can manufacture a chip it needs.

Google chose Intel after months of testing because TSMC is struggling to keep up with AI demand. That sentence is the entire supply chain story in one line.

What This Changes

Intel becoming a credible alternative to TSMC is not just good for Intel. It introduces supplier competition into relationships the entire AI infrastructure trade has been pricing as exclusive.

The Foundry Shift

A confirmed Nvidia-Intel order before SpaceX prices Thursday would be the most consequential chip supply chain announcement of the year. It would arrive into the SpaceX pricing window as evidence the AI demand base is broadening, not concentrating.

Eli Lilly (LLY) released Phase 3 trial data on its next-generation weight-loss drug retatrutide. The results showed average weight loss approaching bariatric surgery outcomes. Even at the lowest dose, results were strong enough that JPMorgan described it as potentially suitable for broad first-line use.

The current generation of GLP-1 drugs like Ozempic and Wegovy already changed how investors think about food, consumer health, and healthcare spending. Retatrutide is categorically better than those. Better outcomes. Better tolerability. The patient stays on it longer.

Medicare coverage for weight-loss drugs begins July 1. The timing converts today's clinical data into near-term revenue rather than a distant projection.

Novo Nordisk (NVO) fell on the news. A competing drug from Zealand Pharma (ZEAL) collapsed more than 20 percent on poor tolerability data the same day. Lilly is pulling further ahead.

The Medicare Moment

July 1 is the largest single demand expansion event in GLP-1 commercial history. Today's data arrives two weeks before that date. The combination of better clinical results and a massive new coverage population is not a 2028 story. It starts next month.

That's not noise. That's capital rushing back into AI.

But here's what smart investors are starting to realize:

AI doesn't run on chips alone. It runs on data.

Mode Mobile sits upstream of this entire shift.

Every model — ChatGPT, copilots, next-gen AI — depends on real human behavior. Clicks. Searches. Usage. That's the fuel. And it's getting harder to find.

Mode has built a 490M+ user data engine powered by real, consented activity. They pay users for screen time — and generate the high-quality data AI companies actually need.

The traction is already there:

Over 59,000 shareholders have already claimed shares. They've secured the $MODE ticker from Nasdaq.

Tap into a $1T opportunity — invest now at just $0.52/share and get up to 20% bonus!

Disclaimer:  Please read the offering circular and related risks at invest.modemobile.com. This is a paid advertisement for Mode Mobile’s Regulation A+ Offering. Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur. The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period.

Campbell Soup (CPB) confirmed today that lower-income consumers are under active stress. Organic sales are falling. The company named the Iran war's energy costs explicitly as a headwind in its forward guidance. Oil at current levels would add meaningful inflation to fiscal 2027 costs. The CFO said the lower end of guidance is "probably more realistic."

Campbell's is not an AI infrastructure company adjusting to rate expectations. It sells soup. When a soup company puts the Iran war in its forward numbers, the energy cost impact has moved from macro abstraction into household reality.

The airline industry told the same story at a larger scale. The global industry trade group forecast airline profits will roughly halve in 2026 as jet fuel costs surge. Jet fuel is up more than 60 percent year-over-year.

Energy costs are moving. First soup. Then flights. Then everything else.

The Forward Signal

Any second consumer staples company updating guidance before Wednesday's CPI and citing today’s renewed Iran exchange as a cost factor would be the clearest confirmation that the military activity has already passed through into corporate cost forecasts. That second name, if it arrives, removes all doubt.

Monday bounced but did not recover.

Iran and Israel halted but the foundation is still cracked. Marvell got a passive demand floor the rest of the sector does not have. Google just broke TSMC's monopoly on AI chip manufacturing. Lilly's new drug showed surgery-level weight loss two weeks before Medicare coverage expands. Campbell's put the Iran war in its guidance.

The bounce was real. The problems are still there.